Article
Immunology
Shengjin Dou, Lin Zhang, Chong Wang, Yanli Yao, Wen Jiang, Lulu Ye, Jiang Li, Sicheng Wu, Debin Sun, Xiaoli Gong, Rongrong Li, Guopei Zhu
Summary: In patients with recurrent or metastatic HNSCC, chromosome 11q13 amplification and EGFR mutations were found to be negatively correlated with decreased PFS and no clinical benefits after PD-1 inhibitor treatment. These markers may serve as potential predictive biomarkers to identify patients for whom immunotherapy may not be suitable.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Sindhu Nair, James A. Bonner, Markus Bredel
Summary: EGFR is overexpressed in head and neck squamous cell carcinoma and anti-EGFR strategies have shown some clinical benefit but often lead to resistance. Mutations in various domains of the EGFR gene can impact drug binding, radiation response, and overall survival in HNSCC patients. Understanding the EGFR mutational landscape and its effects on treatment resistance can help stratify patients for targeted therapies and maximize therapeutic benefits.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Yazan Abu-Shama, Julia Salleron, Florent Carsuzaa, Xu-Shan Sun, Carole Pflumio, Idriss Troussier, Claire Petit, Matthieu Caubet, Arnaud Beddok, Valentin Calugaru, Stephanie Servagi-Vernat, Joel Castelli, Jessica Miroir, Marco Krengli, Paul Giraud, Edouard Romano, Jonathan Khalifa, Melanie Dore, Nicolas Blanchard, Alexandre Coutte, Charles Dupin, Shakeel Sumodhee, Yungan Tao, Vincent Roth, Lionel Geoffrois, Bruno Toussaint, Duc Trung Nguyen, Jean-Christophe Faivre, Juliette Thariat
Summary: A retrospective multicentric study on 322 patients with head and neck cancers of unknown primary (HNCUP) found that neck dissection (ND) improved progression-free survival (PFS) regardless of nodal stage, but did not improve survival rates. The extent of ND did not affect the benefits of the procedure, and the benefits decreased with a more advanced nodal stage.
Article
Medicine, General & Internal
Joo-Leng Low, Dawn Pingxi Lau, Xiaoqian Zhang, Xue-Lin Kwang, Neha Rohatgi, Jane Vin Chan, Fui-Teen Chong, Stephen Qi Rong Wong, Hui-Sun Leong, Matan Thangavelu Thangavelu, Shivaji Rikka, Anders Martin Jacobsen Skanderup, Daniel Shao Weng Tan, Giridharan Periyasamy, Judice Lie Yong Koh, N. Gopalakrishna Iyer, Ramanuj DasGupta
Summary: The study reveals that in the absence of activating EGFR mutations, HNSCC cells may develop resistance to gefitinib through decreased cell proliferation, making them highly vulnerable to cell-cycle inhibitors.
Review
Biochemistry & Molecular Biology
Teresa Magnes, Sandro Wagner, Dominik Kiem, Lukas Weiss, Gabriel Rinnerthaler, Richard Greil, Thomas Melchardt
Summary: Head and neck squamous cell carcinoma is a heterogeneous disease arising from the mucosa of the upper aerodigestive tract, with only about one third of patients responding to checkpoint inhibitors. HPV status and combined positive score are the main biomarkers used in clinical practice, while other factors like tumor mutational burden and immune microenvironment show promise but require validation in prospective trials.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Anne-Sophie Becker, Cornelius Kluge, Carsten Schofeld, Annette Helene Zimpfer, Bjorn Schneider, Daniel Strueder, Caterina Redwanz, Julika Ribbat-Idel, Christian Idel, Claudia Maletzki
Summary: In patients with head and neck squamous cell carcinoma (HNSCC), high expression of CMTM6 is associated with longer overall survival, regardless of treatment. CMTM6 is correlated with other immune markers, and patients with high expression of both CMTM6 and FOXP3 have the longest survival regardless of treatment. PD-L1 positivity is associated with longer progression-free survival, while lower levels of CTLA-4 and FOXP3 may be related to a good response to immunotherapy.
Review
Medicine, General & Internal
Kamila Romanowska, Agnieszka Sobecka, Agnieszka A. Rawluszko-Wieczorek, Wiktoria M. Suchorska, Wojciech Golusinski
Summary: Head and neck squamous carcinoma (HNSCC) is the sixth most prevalent cancer worldwide, with molecular pathogenesis involving cell cycle disorders, intercellular signaling, proliferation, squamous cell differentiation, and apoptosis. In addition to genetic mutations, epigenetic alterations such as DNA methylation and histone modifications play a key role in promoting cancer formation and progression, making them potential biomarkers and therapeutic targets for HNSCC.
Article
Immunology
Qian Long, Chunyu Huang, Qi Meng, Jin Peng, Fan Yao, Dingfu Du, Xiaonan Wang, Wancui Zhu, Dingbo Shi, Xiangdong Xu, Xiang Qi, Wuguo Deng, Miao Chen, Yizhuo Li, Ankui Yang
Summary: By clustering the expression of 46 members of the TNF family, two distinct subtypes with clinical and immune characteristics were identified in HNSCC. A risk scoring system based on the TNF family gene expression profile was constructed, serving as a reliable predictor of overall survival, clinical characteristics, and immune cell infiltration, with potential application as a valuable biomarker for HNSCC immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Thiago Bueno de Oliveira, Alexcia Camila Braun, Ulisses Ribaldo Nicolau, Emne Ali Abdallah, Vanessa da Silva Alves, Victor Hugo Fonseca de Jesus, Vinicius Fernando Calsavara, Luiz Paulo Kowaslki, Ludmilla T. Domingos Chinen
Summary: The study identified the prognostic impact of CTCs and CTM, suggesting their potential role as predictors of ICT benefit in LA-HNSCC.
Article
Oncology
Katie E. Blise, Shamilene Sivagnanam, Grace L. Banik, Lisa M. Coussens, Jeremy Goecks
Summary: There is increasing evidence that the spatial organization of cells within the tumor-immune microenvironment influences survival and response to therapy in various cancer types. This study investigated the spatial proteomics of HPV-negative head and neck squamous cell carcinoma tumors and found that the spatial compartmentalization of neoplastic tumor-immune cells is associated with longer progression free survival. This suggests that spatial organization may have prognostic value in multiple cancer types.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Derek D. Kao, Rocco M. Ferrandino, Joshua M. Bauml, Deborah C. Marshall, Richard Bakst, Scott Roof, Yeun-Hee A. Park, Keith M. Sigel
Summary: This retrospective study compared the effects of timing of prophylactic feeding tube (PFT) and reactive feeding tube (RFT) placement on survival, body weight trends, and hospitalization rates in head and neck cancer patients. The results showed that there was no significant difference in overall survival, body weight changes, and hospitalization rates between PFT and RFT groups after propensity score matching. However, patients who received PFT had lower hospitalization rates compared to those who received RFT.
Review
Cell Biology
Xiaomin Huang, Pascal H. G. Duijf, Sharath Sriram, Ganganath Perera, Sarju Vasani, Lizbeth Kenny, Paul Leo, Chamindie Punyadeera
Summary: Head and Neck cancers (HNC) are a diverse group of upper aero-digestive tract cancer with a high mortality rate. Existing methods for diagnosing and treating HNC mainly rely on cytopathology or histopathology of tumour tissue. However, liquid biopsy, specifically circulating tumour DNA (ctDNA), is emerging as a promising alternative to overcome the challenges of tumour heterogeneity and limited access to tumour tissue. This review focuses on the mechanisms, technological advances, and clinical applications of ctDNA in HNC.
JOURNAL OF BIOMEDICAL SCIENCE
(2023)
Review
Oncology
Farzaneh Kordbacheh, Camile S. Farah
Summary: Head and neck cancer poses a significant burden on global health systems and patients, with traditional treatments including surgery, radiation, and chemotherapy. Targeted immunotherapies have shown significant progress, but rely on understanding molecular pathways. Developing a broader range of targeted therapies is crucial for improving outcomes in head and neck oncology.
Review
Biochemistry & Molecular Biology
Galateia Liouta, Maria Adamaki, Antonis Tsintarakis, Panagiotis Zoumpourlis, Anastasia Liouta, Sofia Agelaki, Vassilis Zoumpourlis
Summary: Head and neck squamous cell carcinoma (HNSCC) is a term used to describe cancers in the head and neck region. Most cases are diagnosed at a late stage and have poor prognosis. DNA methylation has been identified as a potential biomarker for HNSCC, and this study summarizes the current knowledge on how abnormally methylated DNA profiles may contribute to the development and progression of HNSCC, with the aim of improving management and survival outcomes for patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Ting Li, Juan Li, Haitao Wang, Jiayu Zhao, Mingze Yan, Hongjiang He, Shan Yu
Summary: This review highlights the potential of exosomes as biomarkers and therapeutic targets for head and neck squamous cell carcinoma (HNSCC), discussing their biological mechanisms and recent clinical application.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Oncology
Kennedy Yao Yi Ng, Lawrence Wen Jun Wong, Andrea Jing Shi Ang, Ailica Wan Xin Lee, Desiree Shu Hui Tay, Jack Jie En Tan, Sze Huey Tan, Su Pin Choo, David Wai-Meng Tai, Joycelyn Jie Xin Lee
Summary: This study retrospectively analyzed the impact of sequencing tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) therapy in patients with advanced hepatocellular carcinoma (aHCC). The results showed that the sequence of TKI versus ICI therapy did not significantly affect the response rates and safety profiles. This finding is important for patients who are unable to tolerate combination therapy.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Stephanie P. L. Saw, Win Pin Ng, Siqin Zhou, Gillianne G. Y. Lai, Aaron C. Tan, Mei -Kim Ang, Wan-Teck Lim, Ravindran Kanesvaran, Quan Sing Ng, Amit Jain, Wan Ling Tan, Tanujaa Rajasekaran, Johan W. K. Chan, Yi Lin Teh, Mengyuan Pang, Jia-Chi Yeo, Angela Takano, Boon-Hean Ong, Eng-Huat Tan, Sze Huey Tan, Anders J. Skanderup, Daniel S. W. Tan
Summary: The aim of this study was to compare the prognostic value of programmed death-ligand 1 (PD-L1) score in early-stage epidermal growth factor receptor (EGFR)-mutated and EGFR-wildtype non-small cell lung cancer (NSCLC). The results showed that PD-L1 > 1% was an independent predictor of worse prognosis in EGFR-mutated NSCLC and was associated with inferior disease-free survival (DFS) regardless of EGFR status. Therefore, PD-L1 score should be evaluated as a risk stratification factor in prospective adjuvant studies among EGFR-mutated NSCLC.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Yadong Wang, Ling Peng, Ming Zhao, Yuanyuan Xiong, Jianchao Xue, Bowen Li, Zhicheng Huang, Xinyu Liu, Xiaoying Yang, Yang Song, Zhongxing Bing, Chao Guo, Zhenhuan Tian, Chao Gao, Lei Cao, Zhili Cao, Ji Li, Xu Jiang, Xiaoyan Si, Li Zhang, Xiaoguang Li, Zhibo Zheng, Mengmeng Song, Rongrong Chen, Wan-Teck Lim, Alberto Pavan, Atocha Romero, Naixin Liang, Huaxia Yang, Shanqing Li
Summary: The study found no significant differences in TCR repertoire metrics among different KRAS mutation subtypes, but patients with KRAS/STK11 comutation showed a significantly higher MOI compared to STK11 wild type counterparts. Additionally, TCR repertoire metrics were not associated with TMB or PD-L1 expression in KRAS mutant NSCLC.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Review
Oncology
Mangala Hegde, Sosmitha Girisa, Nikunj Naliyadhara, Aviral Kumar, Mohammed S. Alqahtani, Mohamed Abbas, Chakrabhavi Dhananjaya Mohan, Sudha Warrier, Kam Man Hui, Kanchugarakoppal S. Rangappa, Gautam Sethi, Ajaikumar B. Kunnumakkara
Summary: This review focuses on the therapeutic effects of natural compounds targeting nuclear receptors (NRs) in cancer treatment, highlighting their advantages and limitations. The study emphasizes the importance of NRs in gene expression regulation and the potential of natural compounds as oncology drugs.
CANCER AND METASTASIS REVIEWS
(2023)
Editorial Material
Oncology
Aaron C. Tan, Keigo Kobayashi, Stephanie P. L. Saw, Daniel S. W. Tan, Darren Wan-Teck Lim
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Editorial Material
Oncology
Wan Ling Tan, Darren Wan-Teck Lim
JOURNAL OF THORACIC ONCOLOGY
(2023)
Review
Oncology
Brian Sheng Yep Yeo, Harris Jun Jie Muhammad Danial Song, Yoke Lim Soong, Melvin Lee Kiang Chua, Mei-Kim Ang, Darren Wan Teck Lim, Anna See, Chwee Ming Lim
Summary: This study aims to summarize the evidence on the use of anti-PD1 antibodies in recurrent and/or metastatic nasopharyngeal cancer patients and compare their effectiveness with chemotherapy. The results show that anti-PD1 antibodies have significant activity in the treatment of these patients. Combination therapy with gemcitabine and cisplatin enhances the efficacy of treatment.
Article
Multidisciplinary Sciences
Darren Wan-Teck Lim, Hsiang-Fong Kao, Lisda Suteja, Constance H. Li, Hong Sheng Quah, Daniel Shao-Weng Tan, Sze-Huey Tan, Eng-Huat Tan, Wan-Ling Tan, Justina Nadia Lee, Felicia Yu-Ting Wee, Amit Jain, Boon-Cher Goh, Melvin L. K. Chua, Bin-Chi Liao, Quan Sing Ng, Ruey-Long Hong, Mei-Kim Ang, Joe Poh-Sheng Yeong, N. Gopalakrishna Iyer
Summary: This study reports the results of a clinical trial of dual PD-1 and CTLA-4 checkpoint blockade in patients with recurrent/metastatic EBV-positive nasopharyngeal carcinoma. Single-agent checkpoint inhibitor activity is limited in this cancer type, but the combination treatment shows increased activity. The results show that this combination therapy has good tolerability and better clinical response and progression-free survival in patients with low EBV-DNA levels.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Jun Ma, Sze Huey Tan, Daniel Xing Cheng Yin, Nguyen Tuan Anh Tran, Gek San Tan, Gillianne Geet Yi Lai, Mei-Kim Ang, Ravindran Kanesvaran, Amit Jain, Tanujaa Rajasekaran, Eng-Huat Tan, Tony Kiat Hon Lim, Daniel Shao-Weng Tan, Darren Wan-Teck Lim, Quan Sing Ng, Wan Ling Tan
Summary: This study retrospectively examined the performance of osimertinib in the second/subsequent line treatment of lung cancer patients. The results showed that osimertinib had good efficacy in the second-line setting and there was heterogeneity in T790M expression between plasma and tumor tissue, indicating that plasma T790M testing may not fully predict the efficacy of osimertinib.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Review
Biochemistry & Molecular Biology
Kah Yee Goh, Terence You De Cheng, Su Chin Tham, Darren Wan-Teck Lim
Summary: Non-small cell lung cancer (NSCLC) is the dominant form of lung cancer and typically has a poor prognosis. Immunotherapy using immune checkpoint inhibitors (ICI) has shown superior efficacy compared to conventional chemotherapy for advanced NSCLC patients. However, there is a need for biomarkers to accurately predict immunotherapy response, as only a minority of patients benefit from this treatment. Liquid biopsy, which enables non-invasive sampling of blood-based biomarkers, allows for the dynamic monitoring of treatment response. This review summarizes the progress and challenges in identifying circulating biomarkers for predicting immunotherapy benefit in NSCLC patients.
Article
Oncology
Min Hee Yang, Mina Lee, Amudha Deivasigamani, Duc Dat Le, Chakrabhavi Dhananjaya Mohan, Kam Man Hui, Gautam Sethi, Kwang Seok Ahn
Summary: Decanoic acid (DA) has been found to suppress the activation of c-Met and induce apoptosis in hepatocellular carcinoma cells, inhibiting tumor growth and progression. It has also shown anti-tumor effects in preclinical cancer models. Thus, DA has the potential to be a new therapeutic agent for hepatocellular carcinoma.
Meeting Abstract
Oncology
P. L. S. Saw, G. S. Tan, A. Tan, G. Lai, W. C. Tan, E. H. Tan, M-K. Ang, D. W-T. Lim, R. Kanesvaran, Q. S. Ng, A. Jain, W. L. Tan, T. Rajasekaran, J. Chan, Y. L. Teh, S. H. Tan, T. K. H. Lim, D. S. W. Tan
JOURNAL OF THORACIC ONCOLOGY
(2023)